Antithrombotic treatment with and without invasive management is a fundamental component of ACS management. While dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 receptor inhibitor has been consistently shown to reduce recurrent major adverse cardiovascular events in patients with ACS, the combination and time of initiation should reflect the ischaemic and bleeding risk of the patient. Other pharmacological therapies for long term maintenance after an ACS event include high-intensity lipid lowering agents, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers (ARBs) and beta blockers.

Learn more about these drug therapy strategies from Prof. Dr. Kurt Huber. View his presentation from the ACS Forum 2020 webinar and download the accompanying slides for more information. This educational content is relevant for cardiologists, including interventional cardiologists, as well as primary care physicians.

To continue your educational journey, follow the link above to view the complete on-demand video recording of the ACS Forum 2020 webinar. At this link you can also access the accredited e-learning designed around the ACS Forum programme.

The ACS Forum is a medical educational programme supported by an Independent Educational Grant from Amgen.

Prof. Dr Kurt Huber, MD, FESC, FACC, FAHA, is director of the Department of Cardiology and Intensive Care Medicine at the Klinik Ottakring (formerly the Wilhelminen hospital)and Vice Dean of Research and Professor for Acute and Interventional Cardiology at the Sigmund Freud University Medical School, Vienna, Austria. He is an interventional cardiologist with over 35 years of experience. His main research interest covers basic research (mechanisms of thrombus formation and dissolution) as well as clinical research (acute coronary syndromes, organization of STEMI networks, antithrombotic therapy in CV diseases). He has performed over 100 international clinical trials as national coordinator and steering committee member ,has published over800peer reviewed papers, his Hirsh factor is 84 (Thomson Reuters), his lifeIF > 4000, he has organized > 200 national and international conferences, and he has been listed annually from2015-2019among the top0,1% of the most cited researchers globally in ClinicalMedicine.Dr Huber is president of the Austrian Heart Foundation (sinceNovember 2019) and president-elect of the Association of Acute Cardiovascular Care (ACVC) of the EuropeanSociety of Cardiology (ESC )(sinceMarch 2020)

Experts
Prof. Gilles Montalescot, Prof. Dr Kurt Huber, Dr Sergio Raposeiras Roubín, Prof. Dr J. Wouter Jukema, Dr Miklos Rohla, Prof. Dr Jean-Philippe Collet, Prof. Dr Ángel Cequier Fillat, Prof. Dr Jeanine Roeters van Lennep, Prof. Dr Uwe Zeymer, Prof. Dr Giovanni Esposito
  • clock 60 MIN
  • calendar Sep 2021
  • EACCME
This educational programme is supported by an Independent Educational Grant from Amgen
Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Amgen
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
CORONARY CONNECT

CORONARY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Amgen.

Meet the experts

Other programmes of interest

micro-learning Micro learning
Oncology Endocrinology Rare diseases 
Tools for optimising treatment & management of advanced NETs

Maximising outcomes for patients with advanced neuroendocrine tumours 

Experts
Prof. Emily Bergsland, Prof. Louis de Mestier
Endorsed by
NANETS
Neuroendocrine Cancer UK
CommNETs The Healing NET Foundation
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jul 2024

Educational programme supported by an Independent Educational Grant from Ipsen.
podcast Podcast

Episode

2

of 2

episode
Rare diseases Pediatrics Endocrinology 
Short stature: Severe primary IGF-I deficiency (SPIGFD) – Episode 2

Diagnosis and management of classical and non-classical forms of primary IGF-I deficiency and overlapping syndromes

Experts
Prof. Andrew Dauber, Prof. Helen Storr
Endorsed by
The Magic Foundation
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Dec 2023

Educational programme supported by an Independent Educational Grant from Ipsen.
podcast Podcast

Episode

1

of 2

episode
Pediatrics Endocrinology Rare diseases 
Short stature: Key challenges in diagnosis and management – Episode 1

Video podcast exploring primary IGF-I deficiency, GH deficiency and other rare growth disorders

Experts
Prof. Dr. Joachim Woelfle, Prof. Philippe Backeljauw
Endorsed by
The Magic Foundation
  • download Downloadable
    Resources
  • clock 33 MIN
  • calendar Dec 2023

Educational programme supported by an Independent Educational Grant from Ipsen.
interactive-patient-case Interactive patient case

Episode

2

of 2

episode
Cardiology 
Heart failure management in the pre- and post-discharge setting: Case study 2

Optimising multiple drugs concurrently

Experts
Prof. Alexandre Mebazaa
  • clock 15 MIN
  • calendar Oct 2023

This educational programme is supported by an Independent Educational Grant from Roche Diagnostics.
interactive-patient-case Interactive patient case

Episode

1

of 2

episode
Cardiology 
Heart failure management in the pre- and post-discharge setting: Case study 1

Tolerance of guideline-directed medical therapy (GDMT)

Experts
Prof. Alexandre Mebazaa
  • clock 15 MIN
  • calendar Oct 2023

This educational programme is supported by an Independent Educational Grant from Roche Diagnostics.
publication Publication
Oncology Endocrinology 
Acromegaly and Neuroendocrine Tumours Global Survey

Paper published in Advances in Therapy

Endorsed by
Wapo
INCA
  • download Downloadable
    Resources
  • clock 15 MIN
  • calendar Aug 2023

This educational programme is supported by an Independent Educational Grant from Ipsen.